Evaluation of Nanoparticle Aggregation in Human Blood Serum
Evaluation of Nanoparticle Aggregation in Human Blood Serum
复制标题
DOI：
10.1021/bm100971q
复制
发表时间：
2010-11-01
影响因子：
6.2
通讯作者：
Schmidt, Manfred
中科院分区：
文献类型：
--
作者：
Rausch, Kristin;Reuter, Anika;Schmidt, Manfred
在发展的某个阶段，纳米药物或聚合物药物结合物的性能是在体内测试的，也就是在小鼠或大鼠身上。除了药物和化学表征外，这种药物载体系统在大小、大小分布和形状方面的结构表征通常在动物试验之前在生理盐溶液中进行。本文介绍了一种基于动态光散射的监测血清颗粒大小的简单方法。利用不同聚乙二醇化程度的聚乙二醇化多L赖氨酸(PLL-g-PEOx)模型体系，证明了在人血清溶液中可以形成在等渗盐溶液中没有观察到的大聚集体。在聚乙二醇化程度的Scrum溶液和PLL-g-PEOx的混合物中发现了几百纳米大小的聚集体
In a certain stage of development, the performance of nanoparticle- or polymer drug conjugates is tested "in vivo", that is, in mice or rats. Besides pharmaceutical and chemical characterization, the structural characterization of such drug carrier systems in terms of size, size distribution, and shape is typically performed in physiological salt solution prior to animal tests. The present work introduces a simple method based on dynamic light scattering to monitor the particle size in blood serum. Utilizing a model system of pegylated poly-L-lysines (PLL-g-PEOx) of various degrees of pegylation,x, it is demonstrated that large aggregates may form in human serum solution that are not observed in isotonic salt solution. Aggregates of a few hundred nanometers in size were found in mixtures of scrum solution and PLL-g-PEOx with degrees of pegylation